Introduction
Obstructive sleep apnea (OSA) is increasingly recognized as an independent contributor to cardiovascular morbidity through mechanisms involving intermittent hypoxia, oxidative stress, systemic inflammation, and vascular endothelial dysfunction. These interconnected pathways play a central role in the development of hypertension, atherosclerosis, coronary artery disease, heart failure, and stroke.
Intermittent Hypoxia and Oxidative Stress
Recurrent cycles of hypoxia and reoxygenation are the key physiological disturbances in OSA during sleep. This pattern resembles ischemia–reperfusion injury and promotes excessive production of reactive oxygen species (ROS) from multiple sources, including mitochondrial dysfunction, activation of NADPH oxidase, and xanthine oxidase pathways. Elevated ROS levels overwhelm endogenous antioxidant defenses, resulting in oxidative damage to lipids, proteins, and DNA.
Oxidative stress also activates redox-sensitive transcription factors such as nuclear factor kappa B (NF-κB) and hypoxia-inducible factor-1α (HIF-1α), which regulate genes involved in inflammation, vasoconstriction, and vascular remodeling. Increased oxidative burden has been demonstrated in OSA patients and is reduced following effective continuous positive airway pressure (CPAP) therapy.
Systemic Inflammation
OSA is associated with a state of chronic low-grade systemic inflammation. Intermittent hypoxia and sleep fragmentation stimulate sympathetic activation and promote the release of pro-inflammatory mediators. Elevated circulating levels of:
- C-reactive protein (CRP)
- Interleukin-6 (IL-6)
- Tumor necrosis factor-alpha (TNF-α)
- Adhesion molecules (ICAM-1, VCAM-1)
have been consistently reported in patients with moderate to severe OSA.
Inflammation contributes to atherogenesis by enhancing leukocyte adhesion, promoting foam cell formation, and destabilizing atherosclerotic plaques. Importantly, inflammatory biomarkers decrease with CPAP therapy, supporting a causal relationship.
Endothelial Dysfunction
The vascular endothelium is a primary target of oxidative and inflammatory injury in OSA. Endothelial dysfunction is characterized by:
- Reduced nitric oxide (NO) bioavailability
- Impaired endothelium-dependent vasodilation
- Increased endothelin-1–mediated vasoconstriction
- Enhanced platelet activation and thrombogenicity
Flow-mediated dilation studies demonstrate significantly impaired endothelial function in untreated OSA patients, even in the absence of overt cardiovascular disease.
Endothelial dysfunction represents an early and reversible step in the progression to hypertension and atherosclerosis. Several studies show improvement in endothelial function after CPAP therapy or weight reduction.
Integrated Cardiovascular Impact
The combined effects of oxidative stress, inflammation, and endothelial dysfunction lead to:
- Increased arterial stiffness
- Accelerated atherosclerosis
- Elevated systemic vascular resistance
- Prothrombotic state
- Left ventricular remodeling
These mechanisms help explain the strong epidemiologic association between OSA and major adverse cardiovascular events, including myocardial infarction, stroke, atrial fibrillation, and heart failure.
Clinical Implications
Recognition of these pathways highlights OSA as a systemic vascular disease rather than solely a respiratory disorder. Effective treatment strategies—such as CPAP, weight loss, exercise, and emerging neuromodulation therapies—may reduce cardiovascular risk by attenuating oxidative stress and inflammatory burden. Biomarkers of oxidative and inflammatory activity may also serve as tools for cardiovascular risk stratification in sleep-disordered breathing.
References
- Lavie L. Oxidative stress in obstructive sleep apnea and intermittent hypoxia—revisited. Respir Physiol Neurobiol. 2015;209:2–7.
- Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: An American Heart Association scientific statement. Circulation. 2008;118:1080–1111.
- Jelic S, Lederer DJ, Adams T, et al. Vascular inflammation in obesity and sleep apnea. Circulation. 2010;121:1014–1021.
- Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation. 2005;112:2660–2667.
- Drager LF, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: An emerging risk factor for atherosclerosis. Chest. 2011;140:534–542.
- Schulz R, Murzabekova G, Egemnazarov B, et al. Endothelial dysfunction in sleep apnea. J Sleep Res. 2014;23:1–15.
- Marin JM, Carrizo SJ, Vicente E, Agusti AGN. Long-term cardiovascular outcomes in men with obstructive sleep apnea. Lancet. 2005;365:1046–1053.
